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Worldwide, cancer incidence and cancer-
related deaths are steadily rising. According
to the International Agency for Research
on Cancer, new cancer cases rose from
12.7 million in 2008 to 14.1 million in
2012 (1). Similarly, 7.6 million cancer-
related deaths occurred in 2008 compared
to 8.2 million in 2012. A significant pro-
portion of these cases are attributed to
breast cancer, the predominant malignancy
affecting women worldwide. Since 2008,
breast cancer incidence has increased by
over 20% and breast cancer deaths have
risen by 14% (1). Although the incidence
of breast cancer is still highest in developed
countries, women in developing nations
are disproportionately dying as a result
of this disease. Six of the 10 countries
with the highest breast cancer mortality
rate are low- to middle-income countries
(LMICs) (Figure 1). Moreover, breast can-
cer in LMICs often presents when locally
advanced breast cancer (LABC) (2–4) that
can be easily appreciated at physical exam
but is still limited to the breast and drain-
ing lymph nodes, without clinical evidence
of metastatic spread. LABC is defined as
tumors: (1) more than 5 cm in diameter, (2)
involve the skin or the underlying pectoral
muscles, (3) involve axillary, supraclavic-
ular, and/or infraclavicular lymph nodes,
or (4) inflammatory breast cancer. Despite
being confined to the breast and regional
nodes, locally advanced stage often her-
alds the rapid onset of metastatic disease,
explaining high mortality rates. Solutions
are needed to address this health issue.
We propose practical strategies to improve
the early detection of breast cancer and
the treatment of LABC within developing
nations.
DETECTION
In developed countries, national screening
programs have been widely implemented.
Although there are tangible benefits to
mammographic screening, following the
same paradigm in developing nations may
not be ideal or feasible. First, women in
several developing nations are diagnosed
at a younger age than their counterparts in
developed countries. In the United States,
the median age at diagnosis is 61 years old.
In comparison, the median age at diagno-
sis is 50 years old among women in Mex-
ico (5) and 46 years old among Egyptian
women (6). The sensitivity of mammogra-
phy is affected by several factors including
age and breast tissue density. In women
<50 years old, the sensitivity of mammog-
raphy can be as low as 68% (7). Digital
mammography improves the detection of
cancer in younger women but is associ-
ated with higher costs compared to film
mammography. In a study of over 40,000
women, the accuracy of digital mammog-
raphy was significantly higher than that
of film mammography for women under
50 years old, pre- and peri-menopausal
women and those with heterogeneously
dense or extremely dense breasts on mam-
mography (8). Screening mammograms
are performed in women without symp-
toms of breast cancer. Diagnostic mammo-
grams are used to diagnose breast cancer
once suspicious findings have been noted
on screening mammogram or if an indi-
vidual has symptoms suggestive of breast
cancer. Diagnostic mammograms involve
more views of the breast and take longer
to perform. In addition, a radiologist is
present to immediately interpret the exam.
When used for screening or diagnostic
purposes, digital mammograms cost $11
or $33 more per examination, respectively
(9). Restricting the use of digital mam-
mograms to women under 50 years, those
most likely to benefit from a more accurate
assessment of breast densities, would still
prove too expensive for low- to middle-
income nations. According to the World
Health Organization, a cost-effective health
intervention is one to three times a coun-
try’s gross domestic product (GDP) per
capita. Age-targeted digital mammography
would cost $26,500 per quality-adjusted
life year (QALY) (10), well above the cost-
effective threshold for most LMICs.
For developing nations, screening mam-
mography programs are likely cost-
prohibitive with questionable benefits. This
is especially true in populations with a
significant number of young breast can-
cer patients, for whom mammography
is less likely to detect malignancies and
leads to more false-positive results (11–
13). It would be unwise for nations
with limited resources to indiscriminately
adopt the same screening strategy. Finan-
cial resources are likely better invested
in public awareness campaigns and train-
ing community health workers to edu-
cate the public and perform clinical breast
exams (CBE) (2, 14, 15). For example, a
cost-effectiveness analysis of breast can-
cer interventions in Ghana revealed that
mammographic screening of women 40–
69 years old would cost $12,908 per dis-
ability adjusted life year (DALY) averted.
In contrast, biennial CBE and mass media
awareness campaigns would cost $1299 and
$1364 per DALY averted, respectively (16).
Distrust of the medical system and myths
about breast cancer persist, leading women
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Country Mortality Rate (per 100,000 
women)
World Bank Classification
Fiji 28.4 Upper middle income
Bahamas 26.3 High income
Nigeria 25.9 Lower middle income
Pakistan 25.2 Lower middle income
New Caledonia 24.4 High income
Armenia 24.2 Lower middle income
Lebanon 24.0 Upper middle income
Trinidad and Tobago 23.5 High income
Ethiopia 23.0 Low income
Uruguay 22.7 High income
FIGURE 1 | Age-standardized mortality rates, number of deaths per 100,000 women (1).
to rely on traditional healers in lieu of
health centers to their detriment (17, 18).
These issues highlight a critical need to
invest in education.
MULTIMODALITY CARE
Generally, only ~15% of breast cancer
patients in LMICs present with Stage I
breast cancer and 20–40% present with
Stage II disease (19). In sub-Saharan Africa,
40–90% of women present with Stage III–
IV disease (20). The same is true for
low- to middle-income Latin American
countries. In Colombia, 68.2% of patients
present with locally advanced disease and
in Peru and Mexico, approximately 50%
of patients present with advanced disease
(21). Although the 3-year survival rate for
Stage III patients in high-income coun-
tries ranges from 70 to 85%, the survival
rate for patients with comparable stage
of disease is much lower in developing
nations. Optimizing treatment in this sub-
population is part of a reasonable strat-
egy to improve breast cancer mortality in
developing countries.
SURGERY
Surgery plays an important role in the man-
agement of LABC. In developing coun-
tries, modified radical mastectomy (MRM)
continues to be the mainstay of surgical
treatment. In Yemen, approximately 50%
of women undergo MRM and an addi-
tional 10% undergo radical mastectomy
(22). Unfortunately, surgical techniques for
mastectomies are sometimes suboptimal.
In USA and the United Kingdom, most
breast surgeons have undergone surgical
oncology fellowships. In contrast, oppor-
tunities for specialty training are limited
in LMICs. Moreover, quality control pro-
tocols and data regarding mastectomies in
developing countries, including the rate
of negative margins and the number of
lymph nodes excised, are lacking (23).
Studies are needed to assess the qual-
ity of mastectomies and pinpoint areas
for improvement that can lead to better
outcomes.
Fear of deformity is among the mul-
tiple concerns that breast cancer patients
face during treatment (24). Several stud-
ies demonstrated that body image is supe-
rior in women who undergo breast con-
servation therapy (BCT) or mastectomy
with reconstruction rather than those
who have undergone mastectomy without
reconstruction. Interestingly, overall qual-
ity of life is the same for patients whether
they undergo mastectomy with or without
reconstruction, suggesting that satisfaction
with body image is only one component
of global quality of life after breast can-
cer (25). Although providing opportuni-
ties for reconstruction would be ideal, this
should be a lower priority goal in a lim-
ited resource setting, especially since this
procedure can cost between $15,000 and
$50,000.
CHEMOTHERAPY
Neoadjuvant chemotherapy is recom-
mended for women with LABC. In
some cases, neoadjuvant chemotherapy
can significantly shrink the tumor mak-
ing lumpectomy possible. It is essen-
tial that developing nations implement
cost-effective chemotherapeutic regimens.
The WHO Model List of Essential Med-
icines presents a core list of the min-
imum medicine needs for a healthcare
system. In addition, it denotes essential
medicines for diseases like cancer that
require specialized care. Among the 30
cytotoxic and anti-hormonal therapies, the
breast cancer-related agents include carbo-
platin, cyclophosphamide, docetaxel, dox-
orubicin, fluorouracil, methotrexate, pacli-
taxel, and tamoxifen. Provision of these
agents may be a realistic target for upper-
middle-income nations. However, LMICs
may be best served by focusing on access to
three to four of these medications. We pro-
pose paclitaxel, doxorubicin, cyclophos-
phamide, and tamoxifen as the basic
chemotherapeutic elements of breast can-
cer care. Chemotherapy recommendations
according to national resources have also
been published by the Breast Health Global
Initiative (26).
The Academic Model Providing Access
to Healthcare (AMPATH) is a successful
model of chemotherapy delivery in Kenya,
a low-income nation (27). AMPATH is
a collaboration between Moi University
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School of Medicine in Kenya and North
American academic medical centers. Since
2005, cancer care services have been
available and breast cancer represents
over 60% of female-specific malignancies.
The AMPATH Oncology Pharmacy Service
(AOPS) stocks doxorubicin, cyclophos-
phamide, and tamoxifen in addition to
15 other chemotherapy-related agents. AC
chemotherapy appears to be the most
readily available for women in develop-
ing nations. Nearly 50% of patients receiv-
ing neoadjuvant chemotherapy in Ibadan,
Nigeria were treated with doxorubicin
and cyclophosphamide (3). The AOPS
experience also provides other insights
for LMICs regarding issues of cost con-
tainment, personnel training, disposal,
preparation/dispensing, and storage asso-
ciated with chemotherapy. For instance,
by centralizing inventory and monitor-
ing monthly use statistics, AOPS mini-
mized the risk of drug shortages and nego-
tiated better prices. The latter is espe-
cially important because many patients
are uninsured and must bear the total
out-of-pocket costs. Often, patients can-
not afford chemotherapy and will forego
this aspect of treatment. Ntirenganya et al.
reported that 35% of women with breast
masses in Sierra Leone did not seek med-
ical care due to lack of money (18).
By making chemotherapy more afford-
able, healthcare institutions can ensure
that patients are more likely to receive
optimal care thereby improving cancer
outcomes. It will also be necessary to
invest in supportive therapies such as
antiemetics for successful implementation
of chemotherapy.
Another cost-effective strategy is to
combine oophorectomy and hormonal
therapy. In a study of 709 premenopausal
Vietnamese and Chinese women with Stage
IIA–IIIA breast cancer, patients were ran-
domized to undergo oophorectomy at
the time of mastectomy and adjuvant
tamoxifen versus receiving this combined
hormonal treatment at recurrence (28).
At 5 years, oophorectomy and tamoxifen
up front led to a statistically significant
disease-free and overall survival benefit.
Moreover, this intervention cost $350 per
year of life saved.
Targeted agents, such as trastuzumab,
are noticeably absent from the WHO
Model List of Essential Medicines and
likely the pharmacies of most developing
nations. Assessments in Peru, Costa Rica,
and Mexico demonstrate that providing
trastuzumab will cost over $10,000 per
DALY and is consequently not recom-
mended (29, 30). Therefore, unfortunately
HER2-directed therapies should not be
a priority for low- to middle-income
nations.
RADIATION THERAPY
Radiation therapy is an important com-
ponent of care for women with LABC.
Several randomized trials have demon-
strated the local recurrence and mor-
tality benefit associated with adjuvant
radiation therapy after mastectomy (31).
Unfortunately, radiation therapy services
are severely lacking in LMICs. Of 139
LMICs, 55 (39.5%) have no radiation
therapy facilities (32) and 29 of these
are African nations (33). In most high-
income countries, at least one radio-
therapy machine is available for every
250,000 people. In contrast, in nearly 20
LMICs, only one machine is available
for over 5 million people. Ideally, LMICs
should invest in establishing radiation
therapy infrastructure and training per-
sonnel. However, decision-analytic mod-
els estimate that post-mastectomy radi-
ation therapy costs $12,000–$22,600 per
QALY (34, 35). Although this is cost-
effective for most upper-middle-income
countries, it is unlikely to be sustainable
for low to lower-middle-income coun-
tries. Innovative methods are needed to
provide radiation therapy at lower cost
in these developing nations. One strategy
may be to shorten the course of radiation
therapy. Hypofractionated breast radio-
therapy is commonly used after lumpec-
tomy. Although decreasing the total dose
may enhance the therapeutic ratio, pre-
vious studies suggest that 3 Gy per frac-
tion post-mastectomy is associated with
unacceptable brachial plexus toxicity (36).
Additional studies are needed to identify
hypofractionated radiation therapy regi-
mens that can safely treat both the chest
wall and regional lymph nodes.
Concurrent chemoradiation therapy
may also shorten the overall length
and cost of treatment while maintain-
ing treatment efficacy. Among 105 women
treated with neoadjuvant concurrent pacli-
taxel and radiotherapy to the breast and
regional nodes, 34% achieved a patho-
logical response including over 50% of
triple-negative patients (37). Shorten-
ing chemotherapy and radiation therapy
courses also makes treatment more conve-
nient to patients, since patients in LMICs
often have to travel long distances and tem-
porarily live far away from their homes to
undergo treatment.
Finally, simplifying the radiation ther-
apy planning process can reduce the tech-
nical fees and overall cost of radiation ther-
apy. Zhao et al. published their algorithm
for determining the optimal placement
of tangential beams (38). This method
does not require manual beam placement
by physicians, a time-saving feature espe-
cially in developing countries with a lim-
ited number of physicians. Similar meth-
ods for designing regional lymph node
radiotherapy fields are needed.
CONCLUSION
Locally advanced breast cancer contributes
significantly to cancer mortality among
women worldwide. It is particularly impor-
tant to address this disease in developing
nations, where over 70% of all cancer cases
will occur by 2020. There is an overwhelm-
ing need for systematic studies that pin-
point areas of need within the context of
each developing nation and also within
regions in a developing nation. Research in
these settings and dissemination of these
data (39) will guide the judicious use of
available financial and human resources.
In this article, we have suggested strate-
gies for addressing LABC in LMICs. Poten-
tial solutions include (1) investing in CBE
and awareness campaigns, (2) gathering
data and establishing quality control proto-
cols for mastectomies, (3) focusing on the
provision of few but effective chemother-
apeutic agents, and (4) investigating cost
reduction methods for radiation therapy
including shorter regimens.
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